Discover how pharma and biotech are converging in a consumer-driven landscape. Learn about direct-to-patient models, carve-out deals, and why some biotechs are going solo. Get early access to insights from “Pharma v Biotech: New Rules?” and stay ahead of the curve.| Evaluate
Discover how biotech and Big Pharma are evolving under pressure. From China’s R&D surge to pricing reform, we reveal key market shifts that are reshaping the pharma landscape.| Evaluate
Learn how to improve pharmaceutical sales forecasting accuracy. Discover methods, data sources, and eventing techniques to create reliable sales forecasts in pharma.| Evaluate
The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.| Evaluate
Read how a biotech VC firm sharpened investment strategy with data-driven insights, rare disease focus, and lifecycle support| Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore Evaluate’s Q2 2025 biopharma report for the latest insights on M&A, IPOs, venture funding, and China’s rising influence. Essential reading for pharma, biotech, and pharma investors.| Evaluate
BIO International 2025 highlights, including trends in biotech investment, M&A activity, licensing, and the role of China in global biopharma. Download now for expert commentary, market statistics, and strategic guidance.| Evaluate
“Nuclear winter” and “extinction event” were two of the less-than-positive terms used during last month’s BIO International convention to describe the biotech investment landscape..| Evaluate
Pharma industry trends 2025. Find 3 standout insights from Evaluate’s World Preview 2025 webinar, including the rise of integrated biotechs & China’s growing role. Watch now on demand.| Evaluate
